Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Telix Pharmaceuticals ( (AU:TLX) ) has shared an update.
Telix Pharmaceuticals has outlined the safety and dosimetry results from Part 1 of its global Phase 3 ProstACT study (NCT06520345) evaluating TLX591-Tx, a lutetium-177 labeled PSMA-targeting therapy called rosopatamab tetraxetan, in prostate cancer. The data presentation underscores Telix’s strategy to build on its established PSMA-PET imaging franchise by advancing a therapeutic radiopharmaceutical, potentially strengthening its position in prostate cancer care and expanding its portfolio beyond approved diagnostic agents.
The company highlighted that aside from its existing marketed imaging products and the SENSEI device, all other drugs and devices discussed, including TLX591-Tx, Zircaix and Pixclara, remain investigational and lack regulatory approval. This distinction emphasizes both the clinical opportunity and the development risk for stakeholders as Telix seeks to convert its pipeline into commercial therapies within a competitive and tightly regulated oncology market.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$28.50 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a biopharmaceutical company focused on radiopharmaceuticals for imaging and treating cancer and other serious diseases. Its approved products include Illuccix and Gozellix, gallium-68 based PSMA-PET imaging agents for prostate cancer, the bone infection imaging agent Scintimun, and the SENSEI surgical gamma probe, with other candidates such as Zircaix and Pixclara still in development.
YTD Price Performance: -4.02%
Average Trading Volume: 2,834,796
Technical Sentiment Signal: Sell
Current Market Cap: A$3.64B
For an in-depth examination of TLX stock, go to TipRanks’ Overview page.